Clarisse Eveno1, Kelly Mojica1, Justin W Ady1, Daniel L J Thorek2, Valerie Longo3, Laurence J Belin1, Sepideh Gholami1, Clark Johnsen1, Pat Zanzonico3, Nanhai Chen4, Tony Yu4, Aladar A Szalay5, Yuman Fong6. 1. Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY. 2. Division of Nuclear Medicine, Department of Radiology and Radiological Science, The Johns Hopkins School of Medicine, Baltimore, MD. 3. Department of Medical Physics, Memorial Sloan-Kettering Cancer Center, New York, NY. 4. Genelux Corporation, San Diego Science Center, San Diego, CA. 5. Genelux Corporation, San Diego Science Center, San Diego, CA; Department of Biochemistry, University of Würzburg, Würzburg, Germany. 6. Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY. Electronic address: fongy@mskcc.org.
Abstract
BACKGROUND: Peritoneal carcinomatosis (PC) is a terminal progression of colorectal cancer (CRC). Poor response to cytoreductive operation and chemotherapy coupled with the inability to reliably track disease progression by the use of established diagnostic methods, make this a deadly disease. We examined the effectiveness of the oncolytic vaccinia virus GLV-1h153 as a therapeutic and diagnostic vehicle. We believe that viral expression of the human sodium iodide transporter (hNIS) provides both real-time monitoring of viral therapy and effective treatment of colorectal peritoneal carcinomatosis (CRPC). METHODS: Infectivity and cytotoxic effect of GLV-1h153 on CRC cell lines was assayed in vitro. Viral replication was examined by standard viral plaque assays. Orthotopic CRPC xenografts were generated in athymic nude mice and subsequently administered GLV-1h153 intraperitoneally. A decrease in tumor burden was assessed by mass. Orthotopic tumors were visualized by single-photon emission computed tomography/computed tomography after Iodine ((131)I) administration and by fluorescence optical imaging. RESULTS: GLV-1h153 infected and killed CRC cells in a time- and concentration-dependent manner. Viral replication demonstrated greater than a 2.35 log increase in titer over 4 days. Intraperitoneal treatment of orthotopic CRPC xenografts resulted in a substantial decrease in tumor burden. Infection of orthotopic xenografts was therapeutic and facilitated monitoring by (131)I-single-photon emission computed tomography/computed tomography via expression of hNIS in infected tissue. CONCLUSION: GLV-1h153 kills CRC in vitro effectively and decreases tumor burden in vivo. We demonstrate that GLV-1h153 can be used as an agent to provide accurate delineation of tumor burden in vivo. These findings indicate that GLV-1h153 has potential for use as a therapeutic and diagnostic agent in the treatment of CRPC.
BACKGROUND:Peritoneal carcinomatosis (PC) is a terminal progression of colorectal cancer (CRC). Poor response to cytoreductive operation and chemotherapy coupled with the inability to reliably track disease progression by the use of established diagnostic methods, make this a deadly disease. We examined the effectiveness of the oncolytic vaccinia virusGLV-1h153 as a therapeutic and diagnostic vehicle. We believe that viral expression of the humansodium iodide transporter (hNIS) provides both real-time monitoring of viral therapy and effective treatment of colorectal peritoneal carcinomatosis (CRPC). METHODS: Infectivity and cytotoxic effect of GLV-1h153 on CRC cell lines was assayed in vitro. Viral replication was examined by standard viral plaque assays. Orthotopic CRPC xenografts were generated in athymic nude mice and subsequently administered GLV-1h153 intraperitoneally. A decrease in tumor burden was assessed by mass. Orthotopic tumors were visualized by single-photon emission computed tomography/computed tomography after Iodine ((131)I) administration and by fluorescence optical imaging. RESULTS:GLV-1h153 infected and killed CRC cells in a time- and concentration-dependent manner. Viral replication demonstrated greater than a 2.35 log increase in titer over 4 days. Intraperitoneal treatment of orthotopic CRPC xenografts resulted in a substantial decrease in tumor burden. Infection of orthotopic xenografts was therapeutic and facilitated monitoring by (131)I-single-photon emission computed tomography/computed tomography via expression of hNIS in infected tissue. CONCLUSION:GLV-1h153 kills CRC in vitro effectively and decreases tumor burden in vivo. We demonstrate that GLV-1h153 can be used as an agent to provide accurate delineation of tumor burden in vivo. These findings indicate that GLV-1h153 has potential for use as a therapeutic and diagnostic agent in the treatment of CRPC.
Authors: J Esquivel; T C Chua; A Stojadinovic; J Torres Melero; E A Levine; M Gutman; R Howard; P Piso; A Nissan; A Gomez-Portilla; L Gonzalez-Bayon; S Gonzalez-Moreno; P Shen; J H Stewart; P H Sugarbaker; R M Barone; R Hoefer; D L Morris; A Sardi; R P Sticca Journal: J Surg Oncol Date: 2010-11-01 Impact factor: 3.454
Authors: Mohan Hingorani; Christine Spitzweg; Georges Vassaux; Kate Newbold; Alan Melcher; Hardev Pandha; Richard Vile; Kevin Harrington Journal: Curr Cancer Drug Targets Date: 2010-03 Impact factor: 3.428
Authors: Gooitzen M van Dam; George Themelis; Lucia M A Crane; Niels J Harlaar; Rick G Pleijhuis; Wendy Kelder; Athanasios Sarantopoulos; Johannes S de Jong; Henriette J G Arts; Ate G J van der Zee; Joost Bart; Philip S Low; Vasilis Ntziachristos Journal: Nat Med Date: 2011-09-18 Impact factor: 53.440
Authors: Sepideh Gholami; Dana Haddad; Chun-Hao Chen; Nanhai G Chen; Qian Zhang; Pat B Zanzonico; Aladar A Szalay; Yuman Fong Journal: Surgery Date: 2011-12 Impact factor: 3.982
Authors: Laurence J Belin; Justin W Ady; Christina Lewis; Drew Marano; Sepideh Gholami; Kelly Mojica; Clarisse Eveno; Valerie Longo; Pat B Zanzonico; Nanhai G Chen; Aladar A Szalay; Yuman Fong Journal: Surgery Date: 2013-07-23 Impact factor: 3.982
Authors: Silvia Ravera; Andrea Reyna-Neyra; Giuseppe Ferrandino; L Mario Amzel; Nancy Carrasco Journal: Annu Rev Physiol Date: 2017-02-10 Impact factor: 19.318
Authors: Steven J Conrad; Mohamed El-Aswad; Esaw Kurban; David Jeng; Brian C Tripp; Charles Nutting; Robert Eversole; Charles Mackenzie; Karim Essani Journal: J Exp Clin Cancer Res Date: 2015-02-19